OSAKA, May 23 (Kyodo) — Dainippon Sumitomo Pharma Co. said today it will effectively stop a clinical trial on a new colon cancer treatment drug it had hoped to start selling in the United States during the year from next April.
The drugmaker attributed the move to the new drug's underwhelming performance, which the company says it learned through a data analysis conducted during the trial.
The company said it will stop administering the drug to trial participants, adding it knows of no safety-related issues with the drug, which is designed to target cancer stem cells, reported to be responsible for malignant growth.
The move has made it difficult for the company to market the drug in Japan although it had hoped to start doing so during the business year from April 2016.
Dainippon Sumitomo would be forced to review its target of 450 billion yen in sales in the business year through March 2018, a goal it had set with prospective U.S. sales in mind.
A Dainippon Sumitomo official said the drugmaker is examining the potential impact of the latest move on its earnings.